Literature DB >> 25767748

Impact of Cannabis Use on the Development of Psychotic Disorders.

Samuel T Wilkinson1, Rajiv Radhakrishnan1, Deepak Cyril D'Souza2.   

Abstract

The link between cannabis use and psychosis comprises three distinct relationships: acute psychosis associated with cannabis intoxication, acute psychosis that lasts beyond the period of acute intoxication, and persistent psychosis not time-locked to exposure. Experimental studies reveal that cannabis, tetrahydrocannabinol (THC) and synthetic cannabinoids reliably produce transient positive, negative, and cognitive symptoms in healthy volunteers. Case-studies indicate that cannabinoids can induce acute psychosis which lasts beyond the period of acute intoxication but resolves within a month. Exposure to cannabis in adolescence is associated with a risk for later psychotic disorder in adulthood; this association is consistent, temporally related, shows a dose-response, and is biologically plausible. However, cannabis is neither necessary nor sufficient to cause a persistent psychotic disorder. More likely it is a component cause that interacts with other factors to result in psychosis. The link between cannabis and psychosis is moderated by age at onset of cannabis use, childhood abuse and genetic vulnerability. While more research is needed to better characterize the relationship between cannabinoid use and the onset and persistence of psychosis, clinicians should be mindful of the potential risk of psychosis especially in vulnerable populations, including adolescents and those with a psychosis diathesis.

Entities:  

Keywords:  Cannabis; psychosis; psychotic disorders; schizophrenia

Year:  2014        PMID: 25767748      PMCID: PMC4352721          DOI: 10.1007/s40429-014-0018-7

Source DB:  PubMed          Journal:  Curr Addict Rep


  166 in total

1.  Cannabis, cognition, and residual confounding.

Authors:  Harrison G Pope
Journal:  JAMA       Date:  2002-03-06       Impact factor: 56.272

2.  Neuropsychological performance in long-term cannabis users.

Authors:  H G Pope; A J Gruber; J I Hudson; M A Huestis; D Yurgelun-Todd
Journal:  Arch Gen Psychiatry       Date:  2001-10

3.  Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential.

Authors:  Sherrica Tai; William E Fantegrossi
Journal:  Curr Addict Rep       Date:  2014-06-01

4.  Executive dysfunction in substance dependent individuals during drug use and abstinence: an examination of the behavioral, cognitive and emotional correlates of addiction.

Authors:  Antonio Verdejo-García; Antoine Bechara; Emily C Recknor; Miguel Pérez-García
Journal:  J Int Neuropsychol Soc       Date:  2006-05       Impact factor: 2.892

5.  Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex.

Authors:  S M Eggan; D S Melchitzky; S R Sesack; K N Fish; D A Lewis
Journal:  Neuroscience       Date:  2010-06-11       Impact factor: 3.590

6.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

Review 7.  Role of endogenous cannabinoids in synaptic signaling.

Authors:  Tamas F Freund; Istvan Katona; Daniele Piomelli
Journal:  Physiol Rev       Date:  2003-07       Impact factor: 37.312

Review 8.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Authors:  Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

9.  Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.

Authors:  Patrik Roser; Georg Juckel; Johannes Rentzsch; Thomas Nadulski; Jürgen Gallinat; Andreas M Stadelmann
Journal:  Eur Neuropsychopharmacol       Date:  2008-06-10       Impact factor: 4.600

Review 10.  Cannabidiol as a potential treatment for psychosis.

Authors:  C D Schubart; I E C Sommer; P Fusar-Poli; L de Witte; R S Kahn; M P M Boks
Journal:  Eur Neuropsychopharmacol       Date:  2013-11-15       Impact factor: 4.600

View more
  27 in total

1.  mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.

Authors:  Martin Engel; Peta Snikeris; Natalie Matosin; Kelly Anne Newell; Xu-Feng Huang; Elisabeth Frank
Journal:  Psychopharmacology (Berl)       Date:  2016-02-10       Impact factor: 4.530

2.  Astrocytic Mechanisms Involving Kynurenic Acid Control Δ9-Tetrahydrocannabinol-Induced Increases in Glutamate Release in Brain Reward-Processing Areas.

Authors:  Maria E Secci; Paola Mascia; Claudia Sagheddu; Sarah Beggiato; Miriam Melis; Andrea C Borelli; Maria C Tomasini; Leigh V Panlilio; Charles W Schindler; Gianluigi Tanda; Sergi Ferré; Charles W Bradberry; Luca Ferraro; Marco Pistis; Steven R Goldberg; Robert Schwarcz; Zuzana Justinova
Journal:  Mol Neurobiol       Date:  2018-08-27       Impact factor: 5.590

Review 3.  Cannabis use among U.S. adolescents in the era of marijuana legalization: a review of changing use patterns, comorbidity, and health correlates.

Authors:  Christopher J Hammond; Aldorian Chaney; Brian Hendrickson; Pravesh Sharma
Journal:  Int Rev Psychiatry       Date:  2020-02-06

Review 4.  Using Evolutionary Theory to Guide Mental Health Research.

Authors:  Zachary Durisko; Benoit H Mulsant; Kwame McKenzie; Paul W Andrews
Journal:  Can J Psychiatry       Date:  2016-02-12       Impact factor: 4.356

Review 5.  Different Paths to Core Pathology: The Equifinal Model of the Schizophrenia Syndrome.

Authors:  Isobel W Green; Jill R Glausier
Journal:  Schizophr Bull       Date:  2015-09-20       Impact factor: 9.306

6.  Cannabis Consumption in People Living with HIV: Reasons for Use, Secondary Effects, and Opportunities for Health Education.

Authors:  Cecilia T Costiniuk; Zahra Saneei; Syim Salahuddin; Joseph Cox; Jean-Pierre Routy; Sergio Rueda; Sara J Abdallah; Dennis Jensen; Bertrand Lebouché; Marie-Josée Brouillette; Marina Klein; Jason Szabo; Charles Frenette; Andreas Giannakis; Mohammad-Ali Jenabian
Journal:  Cannabis Cannabinoid Res       Date:  2019-09-23

7.  Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed.

Authors:  Margaret Haney; A Eden Evins
Journal:  Neuropsychopharmacology       Date:  2015-08-19       Impact factor: 7.853

8.  Concurrent and Sustained Cumulative Effects of Adolescent Marijuana Use on Subclinical Psychotic Symptoms.

Authors:  Jordan Bechtold; Alison Hipwell; David A Lewis; Rolf Loeber; Dustin Pardini
Journal:  Am J Psychiatry       Date:  2016-05-03       Impact factor: 18.112

Review 9.  Cannabis and development of dual diagnoses: A literature review.

Authors:  Rebecca C Hanna; Jessica M Perez; Subroto Ghose
Journal:  Am J Drug Alcohol Abuse       Date:  2016-09-09       Impact factor: 3.829

10.  Cannabinoids: is there a potential treatment role in epilepsy?

Authors:  Robert E Blair; Laxmikant S Deshpande; Robert J DeLorenzo
Journal:  Expert Opin Pharmacother       Date:  2015-08-03       Impact factor: 3.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.